19 completed, 4 withdrawn, 2 terminated, 1 active not recruiting. 17 Phase 2, 11 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 11, Withdrawn 3, Terminated 2, Active not recruiting 1 |
| Phase 1 | 11 | Completed 9, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow bavituximab: new trials by email Literature Review of bavituximab trials Research Report on bavituximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Axitinib, Avelumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2022-11-04 | 2023-05-03 |
| 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Bavituximab, Pembrolizumab - Squamous Cell Carcinoma | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 7 | 2020-01-13 | 2026-02-19 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Bavituximab, Pembrolizumab Injection - Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Completed | OncXerna Theraputics, Inc. | 80 | 2019-09-11 | 2023-02-08 |
| A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Pembrolizumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Completed | David Hsieh | 35 | 2018-04-26 | 2026-07-08 |
| Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Temozolomide, Bavituximab, Radiation - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 36 | 2017-09-13 | 2024-05-16 |
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab - HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma | Phase 1 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-27 | 2020-06-05 | |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer Bavituximab, Taxane - Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-03-01 | 2017-03-09 | |
| Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer durvalumab, bavituximab - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-02-01 | 2016-08-01 | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Bavituximab, Taxane - Metastatic Breast Cancer | Phase 2 / Phase 3 | Withdrawn | Peregrine Pharmaceuticals | 2015-12-01 | 2017-07-11 | |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer bavituximab, Docetaxel, Placebo (for bavituximab) - Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV | Phase 3 | Completed | Peregrine Pharmaceuticals | 582 | 2013-12-01 | 2017-04-21 |
| A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma Radiation, Bavituximab, Capecitabine - Rectal Adenocarcinoma | Phase 1 | Completed | University of Texas Southwestern Medical Center | 15 | 2012-08-08 | 2020-08-20 |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer Cabazitaxel plus bavituximab - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 4 | 2011-06-01 | 2018-07-13 |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects Bavituximab - Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 26 | 2011-05-01 | 2018-12-04 |
| Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection Bavituximab, Pegylated interferon (PEG-IFN) - Hepatitis C | Phase 1 / Phase 2 | Completed | Peregrine Pharmaceuticals | 66 | 2011-01-01 | 2012-02-06 |
| Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer bavituximab, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 70 | 2011-01-01 | 2017-04-19 |
| Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 47 | 2011-01-01 | 2020-11-12 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer paclitaxel, bavituximab, laboratory biomarker analysis - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer | Phase 1 | Completed | University of Arizona | 14 | 2011-01-01 | 2016-04-21 |
| Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer Docetaxel plus bavituximab or placebo - Non-small-cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 121 | 2010-06-01 | 2017-04-19 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer Paclitaxel / Carboplatin, bavituximab - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 86 | 2010-06-01 | 2017-04-19 |
| Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Bavituximab - Carcinoma Breast Stage IV | Phase 2 | Completed | Peregrine Pharmaceuticals | 46 | 2008-07-01 | 2011-03-24 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Breast Neoplasms (5) · Carcinoma, Hepatocellular (4) · Hepatitis C (4) · Liver Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Squamous Cell (1) · Fibrosis (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · HIV Infections (1) · Hepatitis (1) · Liver Diseases (1)
Peregrine Pharmaceuticals (15) · University of Texas Southwestern Medical Center (3) · David Hsieh (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Massachusetts General Hospital (1) · Medical University of South Carolina (1) · OncXerna Theraputics, Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Arizona (1) · University of Maryland, Baltimore (1)
United States (20) · Georgia (4) · India (4) · Ukraine (4) · Russia (3) · South Korea (2) · Taiwan (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Romania (1)
David Hsieh, MD (2) · Adam C Yopp, MD (1) · Alison Stopeck (1) · David E Gerber, MD (1) · David Page, MD (1) · Eliot W Godofsky, MD (1) · Eliot W Godofsky, MD, FACP (1) · Elizabeth R Gerstner, MD (1) · Eric Lawitz, MD (1) · Janet Nuttall, MPH (1) · Jessica Frakes, M.D. (1) · Jihad Slim, MD (1) · Jorge Rodriguez, MD (1) · Juneko Grilley Olson, MD (1) · Kathy Miller, MD (1)
PMID 18784101, PMID 25236982, PMID 29767677, PMID 31429027, PMID 37327319, PMID 38467639, PMID 42346219
2015 (1), 2019 (1), P30CA023074 (1)